Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.

Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK.

BMC Cancer. 2019 Jun 19;19(1):603. doi: 10.1186/s12885-019-5795-x.

2.

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3.

PMID:
31029646
3.

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.

Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.

4.

Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.

Yu JQ, Doss M, Alpaugh RK.

PET Clin. 2018 Apr;13(2):249-268. doi: 10.1016/j.cpet.2017.11.009. Review.

PMID:
29482753
5.

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.

Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM.

Nat Commun. 2017 Dec 19;8(1):2193. doi: 10.1038/s41467-017-02320-7.

6.

Circulating tumor cells: silent predictors of metastasis.

Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK.

F1000Res. 2017 Aug 14;6. pii: F1000 Faculty Rev-1445. doi: 10.12688/f1000research.11313.1. eCollection 2017. Review.

7.

NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.

MacFarlane AW 4th, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, Millenson MM, Al-Saleem T, Cohen AD, Campbell KS.

Oncoimmunology. 2017 May 19;6(7):e1330235. doi: 10.1080/2162402X.2017.1330235. eCollection 2017.

8.

Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining.

Adams DL, Alpaugh RK, Tsai S, Tang CM, Stefansson S.

Sci Rep. 2016 Sep 20;6:33488. doi: 10.1038/srep33488.

9.

Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions.

Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42. doi: 10.1158/1055-9965.EPI-15-1221. Epub 2016 May 17.

10.

Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas.

Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Breast Cancer Res. 2016 May 4;18(1):44. doi: 10.1186/s13058-016-0706-4.

11.

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.

Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ.

Pancreas. 2016 Sep;45(8):1131-5. doi: 10.1097/MPA.0000000000000619.

12.

Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells.

Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S, Tang CM, Stefansson S.

RSC Adv. 2016;6(8):6405-6414. doi: 10.1039/c5ra21524b. Epub 2016 Jan 11.

13.

Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.

Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Cytometry A. 2015 Feb;87(2):137-44. doi: 10.1002/cyto.a.22613. Epub 2014 Dec 16.

14.

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.

Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA.

Breast Cancer Res Treat. 2014 Jul;146(1):145-52. doi: 10.1007/s10549-014-3008-5. Epub 2014 Jun 6.

PMID:
24903226
15.

Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers.

Doss M, Kolb HC, Walsh JC, Mocharla VP, Zhu Z, Haka M, Alpaugh RK, Chen DY, Yu JQ.

Mol Imaging Biol. 2014 Oct;16(5):739-46. doi: 10.1007/s11307-014-0730-7.

PMID:
24696183
16.

Circulating giant macrophages as a potential biomarker of solid tumors.

Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9. doi: 10.1073/pnas.1320198111. Epub 2014 Feb 18.

17.

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M.

J Clin Oncol. 2014 Sep 1;32(25):e88-91. doi: 10.1200/JCO.2013.49.0599. Epub 2014 Feb 10. No abstract available.

18.

A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.

Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.

19.

Phase II trial of vorinostat in advanced melanoma.

Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A.

Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25.

PMID:
24464266
20.

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M.

Clin Breast Cancer. 2014 Feb;14(1):e14-6. doi: 10.1016/j.clbc.2013.09.010. Epub 2013 Sep 27. No abstract available.

PMID:
24201163
21.

Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.

Doss M, Kolb HC, Walsh JC, Mocharla V, Fan H, Chaudhary A, Zhu Z, Alpaugh RK, Lango MN, Yu JQ.

J Nucl Med. 2013 Dec;54(12):2087-92. doi: 10.2967/jnumed.113.119800. Epub 2013 Oct 17.

22.

An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression.

Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, Donahue G, Sands J, Gumbs AA, Zaret KS.

Cell Rep. 2013 Jun 27;3(6):2088-99. doi: 10.1016/j.celrep.2013.05.036. Epub 2013 Jun 20. Erratum in: Cell Rep. 2013 Jul 25;4(2):403. Rhimm, Andrew D [corrected to Rhim, Andrew D].

23.

Inflammatory breast cancer (IBC): clues for targeted therapies.

Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M.

Breast Cancer Res Treat. 2013 Jul;140(1):23-33. doi: 10.1007/s10549-013-2600-4. Epub 2013 Jun 21.

24.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK.

Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13.

25.

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK.

Gynecol Oncol. 2012 Dec;127(3):538-43. doi: 10.1016/j.ygyno.2012.08.020. Epub 2012 Aug 23. Erratum in: Gynecol Oncol. 2013 Jul;130(1):252-3.

26.

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK.

Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16.

27.

Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.

Doss M, Kolb HC, Zhang JJ, Bélanger MJ, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ.

J Nucl Med. 2012 May;53(5):787-95. doi: 10.2967/jnumed.111.088955. Epub 2012 Apr 12.

28.

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.

Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM.

Cancer Immunol Immunother. 2012 Jan;61(1):49-61. doi: 10.1007/s00262-011-1090-7. Epub 2011 Aug 13.

29.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.

Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

30.

Modified skin-window technique in cynomolgus macaques (Macaca fasicularis) for assessing neutrophil extravasation.

Maguire S, Dobrzynski E, Alpaugh RK.

J Am Assoc Lab Anim Sci. 2010 Jul;49(4):475-9.

31.

Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ.

Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a.

32.

Naptumomab estafenatox: a new immunoconjugate.

Robinson MK, Alpaugh RK, Borghaei H.

Expert Opin Biol Ther. 2010 Feb;10(2):273-9. doi: 10.1517/14712590903575620. Review.

PMID:
20053143
33.

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.

Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD.

Pancreas. 2008 Aug;37(2):154-8. doi: 10.1097/MPA.0b013e31816618ce.

PMID:
18665076
34.

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM.

J Immunol. 2008 May 1;180(9):6392-401.

35.

Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development.

Urtishak S, Alpaugh RK, Weiner LM, Swaby RF.

Biomark Med. 2008 Apr;2(2):137-45. doi: 10.2217/17520363.2.2.137.

PMID:
20477435
36.

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM.

J Immunol. 2007 Sep 1;179(5):2815-23.

37.

Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.

Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM.

J Immunother. 2007 May-Jun;30(4):455-67.

PMID:
17457220
38.

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ.

Clin Colorectal Cancer. 2006 Jul;6(2):125-32.

PMID:
16945168
39.

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.

Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM.

J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7.

40.

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A.

J Clin Oncol. 2004 Feb 15;22(4):602-9.

PMID:
14966084
41.

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ.

Cancer Chemother Pharmacol. 2004 Jun;53(6):513-8. Epub 2004 Feb 3.

PMID:
14760509
42.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ.

J Clin Oncol. 2003 Apr 1;21(7):1301-6.

PMID:
12663718
43.

Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.

Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM.

Cancer Res. 2002 Aug 15;62(16):4767-72.

44.

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM.

Cancer Res. 2001 Jun 15;61(12):4750-5.

45.

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.

Clin Cancer Res. 2001 May;7(5):1181-91.

46.

Overview of clinical trials employing antibody-targeted superantigens.

Persson B, Persson R, Weiner LM, Alpaugh RK.

Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):143-152.

PMID:
10837622
47.

Production and characterization of mice transgenic for the A and B isoforms of human FcgammaRIII.

Amoroso AR, Alpaugh RK, Barth MW, McCall AM, Weiner LM.

Cancer Immunol Immunother. 1999 Nov;48(8):443-55.

PMID:
10550549
48.

Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.

Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP.

Med Oncol. 1998 Sep;15(3):191-8.

PMID:
9819796
49.

Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.

Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R, Burnite M, Nielsen SE, Vitek L, Persson B, Weiner LM.

Clin Cancer Res. 1998 Aug;4(8):1903-14.

50.

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins.

Weiner LM, Alpaugh RK, von Mehren M.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):190-2.

PMID:
9435871

Supplemental Content

Loading ...
Support Center